DAP3 and colon adenocarcinoma: Bevacizumab functions as an inhibitor of tumor angiogenesis; therefore, a panel of biomarkers was applied to investigate the correlation between DAP3 and neovascularization in the TCGA-Colon Adenocarcinoma dataset (94).